- Home
- ICUCW vs OSRHW Comparison
ICUCW vs OSRHW Comparison
Compare ICUCW & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICUCW | OSRHW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 18 | 21 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ICUCW | OSRHW |
|---|---|---|
| Price | $0.03 | $0.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 29.5K | 27.3K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.03 |
| 52 Week High | $0.05 | $0.08 |
Technical Indicators
Market Signals| Indicator | ICUCW | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 49.62 |
| Support Level | $0.02 | $0.04 |
| Resistance Level | $0.05 | $0.06 |
| Average True Range (ATR) | 0.01 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 86.67 | 50.98 |
Price Performance
Historical ComparisonAbout ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About OSRHW OSR Holdings Inc. Warrant
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.